

Validation Platform for Al in Pathology Imaging

VAL P Validation Platform for Al in Pathology Imaging

Affiliations

- Kevin Sandeman
 - Head of Unit, Pathology laboratory Malmö, Clinical genetics, pathology and molecular diagnostics, Medicinsk Service, Region Skåne




Background


- Artificial intelligence (AI) shows great potential
 - Registered products on the market
 - Barely any AI-innovations i clinical pathology: AI-algorithms show mainly local success
- Need for clinical general validation
 - Patient safety and clinical effectivity should be guaranteed
 - Lesser regions lack resources for validation process
- National cooperation to share the resources with the inclusion of lesser laboratories
 - Design a national database with a rich variation of material necessary for validation


Our main goal is to promote acceptance for AI-solutions in the clinical workflow.


Background

- Vinnova/Medtech4Health financed project
- Support health care organizations in their responsibility to control effective and patient safe implementation of AI solutions
- National validation platform for AI
 - Guarantee validation capacity in health care and safe effective clinical implementation












VAI.P






VAI.P




VAI.P



VAI-P

• Test


- 2 secure platforms
- Upload of data
- Al-implementations
- Data analysis, surveillance and reporting strategies
- Academic question
 - Ki67 implementation




VAI-P

• Test

- 2 secure platforms
- Upload of data
- Al-implementations
- Data analysis, surveillance and reporting strategies
- Academic question
 - Ki67 implementation






Academic Question:

- Clinical challenges
 - Interobserver variation
 - Global Ki67 takes +/- 9 min per case
- AI promises
 - Less interobserver variation
 - Faster calculation (10-20x faster)


Li, L., Han, D., Yu, Y. et al. Artificial intelligence-assisted interpretation of Ki-67 expression and repeatability in breast cancer. Diagn Pathol 17, 20 (2022). https://doi.org/10.1186/s13000-022-01196-6

Ki67 implementation





Explainability


- Central for pathologists in their workflow
 - In comparison to HE and IHC slides























Cooperations

Regions/Universities	Pathology Platforms	AI-providers	Stakeholders
Skåne	Sectra	Aiforia	Vinnova/MedTech4Health
Östergötland	Proscia	Visiopharm	AIDA
Västerbotten			MT (SKR)
LU			KVAST

Progress

Achievements: Fall/ winter 2023

- Clinical validation studies
 - Data from five laboratories
 - 2 platforms
 - 2 Al-providers
 - 15 swedish pathologist with each 20 cases to assess
- Communication/interest between scandinavian laboratories

Goal: Spring 2024

• Final report

Questions/ Challenges

Ethical approval – continuous supervision of multiple AI-products

• Ethical approval for patient data management

Platform design has support for:

- automated data gathering and testing.
- easy integration of AI-products.
- validation against specific dependent parameters.

Clinical workflow is central

- Pathology competence is central
- Explainability for pathologists or strong validation by laboratory.
- Stepwise integration without central role for AI-results (prioritization).
- Feedback loop to retrain AI-solutions.









Håkan Olsson Hakan.H.Olsson@skane.se +46 735 55 35 03 Andreas Malm Andreas.Malm@skane.se +46 733 35 65 81 Jurko Zoric Jurko.Zoric@skane.se +46 768 87 14 84

Kevin Sandeman Kevin.Sandeman@skane.se +46 40 33 16 19